Dr. Pankaj Mohan founded Sonnet in 2015 and currently serves as Chief Executive Officer and Chairman. He is also a member of the Board of Directors of Outlook Therapeutics, Inc. which he also founded (formerly known as Oncobiologics). From January 2011 to June 2018, he served as Oncobiologics’ President, Chief Executive Officer, and Chairman. Previously, Dr. Mohan served as head of Business Operations and Portfolio Management of Biologics Process and Product Development at Bristol-Myers Squibb Company and as a Director of Bioprocess Engineering at Genentech, Inc. Prior to that Dr. Mohan served as a senior manager at Eli Lilly and Company. From May 1993 to April 1996, Dr. Mohan served as Assistant Professor (Lecturer/Fellow) at the Advanced Centre for Biochemical Engineering, University College London, London, United Kingdom.

Dr. Mohan received a Doctor of Philosophy in Biochemical Engineering from the School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom, a master’s in financial management from Middlesex University Business School, London, United Kingdom, and a bachelor’s degree in chemical engineering from the Indian Institute of Technology in Roorkee, India. Dr. Mohan also attended an Executive Management Program (AMP) from Fuqua School of Business at Duke University.

Jay Cross joined Sonnet BioTherapeutics in May 2019 and serves as the Chief Financial Officer. Prior to Sonnet, Mr. Cross was a Managing Director with Chardan Capital’s healthcare investment banking team, where he focused on biopharmaceuticals. From 2002 to 2014, Mr. Cross worked as an analyst and portfolio manager specializing in therapeutics for several global institutional investment firms. He launched his career in finance in 1999 as an associate analyst covering biotechnology on the healthcare equity research team at Hambrecht & Quist.

Mr. Cross earned a Master of Public Health from the Yale University School of Medicine and a Bachelor of Science in psychology from Washington & Lee University.

Dr. John Cini is Chief Scientific Officer and a Co-Founder of Sonnet BioTherapeutics, where he oversees and directs the company’s discovery and development programs. His role includes the oversight of the selection process of cancer and immune-oncology targets and proof-of-concept testing.

Prior to joining Sonnet, he was Vice President of Discovery and Development Sciences at Oncobiologics. He has successfully advanced more than 20 novel monoclonal antibody products from discovery to IND. He is the holder of several novel product and formulation patents and applications. He has been directly involved in several successful novel biologics through early discovery research into development and manufacturing through clinical trials and commercialization.

Previous positions include Executive Director at Mederex (acquired by Bristol-Myers Squibb in 2010), lead discovery scientific roles at Johnson & Johnson (Ethicon, OrthoBioTech & Pharmaceutical Research), and Bayer. Dr. Cini’s therapeutic areas of expertise in system biology including -oncology, immune-oncology, inflammation, osteoporosis, wound healing, surgical adhesion, and cellular aging.

Susan Dexter serves as Sonnet’s Chief Technical Officer. She comes to Sonnet with more than twenty-five years in biotechnology science, manufacturing and business development. Susan’s experience includes management of biotechnology contract manufacturing services ranging from process development through commercial manufacturing, and strategic consulting related services. Her prior roles include Managing Director, Latham Biopharm Group; Chief Business Officer at Xcellerex, Inc.; VP of Business Development at The Dow Chemical Company; Assoc. Director of Business Development, Celltech and Lonza.

Ms. Dexter holds a double major with Honors in Immunology and Marketing from American University, Washington, D.C.

Dr. Kenney has more than 20 years of experience in translational-stage development of biologics, as well as the commercialization strategy and corporate management of preclinical, clinical-stage and commercialized vaccines and immunotherapies. As President of ClinReg Biologics, he has provided strategic consulting in clinical and regulatory affairs of biologics, medical monitoring and pharmacovigilance in several capacities. Dr. Kenney most recently served as Chief Development Officer at X-VAX Technology and previously held Chief Medical Officer roles at Immune Design and Crucell Holland, where he led the clinical development and regulatory affairs groups. Dr. Kenney was a researcher/reviewer for the FDA for over six years and did post-graduate training at Duke and NIH. Dr. Kenney received a B.S. in Chemistry from George Washington University and his M.D. from Harvard Medical School.

Dr. Stephen J. McAndrew currently serves as the Senior Vice President of Business Development at Sonnet BioTherapeutics, headquartered in Princeton, New Jersey.  Prior to joining Sonnet, from March 2014 to October 2019, Dr. McAndrew served as the Senior Vice President of Business Strategy & Development and from February 2012 to March 2014, served as the Vice President of Business Development at Oncobiologics, Inc.. From March 2011 to February 2012, Dr. McAndrew served as the President of SJM Biopharma Consulting, LLC, a biopharmaceutical consulting company.  From December 2009 to March 2011, Dr. McAndrew served as the Vice President of Scientific Commercial Development at Taconic Biosciences, Inc., a contract research and biotechnology company, and from August 2007 to December 2009, Dr. McAndrew served as the Vice President of Business Development at Caliper Life Sciences, Inc., a biotechnology company, and prior to that, from January 2004 to August 2007, Dr. McAndrew served as Vice President of Business Development at Xenogen Biosciences Corporation, a provider of in vivo drug discovery services.  From January 2001 to December 2003, Dr. McAndrew served as the Vice President of Pharmaceutical Business Development at Lexicon Pharmaceuticals, Inc., a biopharmaceutical drug discovery and development company.  Prior to that, from March 1993 to December 2001, Dr. McAndrew served in various positions of increasing responsibility at Bristol-Myers Squibb Company, including as the Director of Biotechnology Licensing within the External Science and Technology (“EST”) Department.

Dr. McAndrew earned his Ph.D. in Molecular and Cellular Biology from Ohio University, an M.S in Molecular Genetics from the State University of New York at Albany and a B.S from the State University of New York at Oswego, and since completing his formal education, has directed exploratory research programs while at Hoffmann-La Roche in Nutley, New Jersey from 1980 to 1986 and then went on to direct specific research programs while in Oncology Drug Discovery at Bristol-Myers Squibb in the early to mid-90’s.  Responsibilities include monitoring and evaluating key developments and trends in biomedical research, working with internal scientific management to establish strategic technology needs and priorities, managing a program to source and evaluate technologies that complement or supplement ongoing research activities, negotiating and structuring agreements to acquire or access those technologies, securing management approval and execution of agreements, and managing post-execution alliance issues.